These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27860204)

  • 1. Angelman syndrome: Current and emerging therapies in 2016.
    Tan WH; Bird LM
    Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):384-401. PubMed ID: 27860204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological therapies for Angelman syndrome.
    Tan WH; Bird LM
    Wien Med Wochenschr; 2017 Jun; 167(9-10):205-218. PubMed ID: 26758979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
    Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
    Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
    Tsagkaris C; Papakosta V; Miranda AV; Zacharopoulou L; Danilchenko V; Matiashova L; Dhar A
    Curr Gene Ther; 2020; 19(6):359-366. PubMed ID: 31914913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
    Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
    Mol Autism; 2018; 9():45. PubMed ID: 30140420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome.
    Copping NA; McTighe SM; Fink KD; Silverman JL
    Neurotherapeutics; 2021 Jul; 18(3):1535-1547. PubMed ID: 34528170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angelman syndrome: current approach and the future of therapies].
    Sell E; Heymans J
    Medicina (B Aires); 2024 Sep; 84 Suppl 3():15-20. PubMed ID: 39331770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Nociception in Angelman Syndrome Model Mice.
    McCoy ES; Taylor-Blake B; Aita M; Simon JM; Philpot BD; Zylka MJ
    J Neurosci; 2017 Oct; 37(42):10230-10239. PubMed ID: 28931574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome.
    Elgersma Y; Sonzogni M
    Dev Med Child Neurol; 2021 Jul; 63(7):802-807. PubMed ID: 33543479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angelman syndrome - insights into a rare neurogenetic disorder.
    Buiting K; Williams C; Horsthemke B
    Nat Rev Neurol; 2016 Oct; 12(10):584-93. PubMed ID: 27615419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice.
    Li J; Shen Z; Liu Y; Yan Z; Liu Y; Lin X; Tang J; Lv R; Geng G; Xiong ZQ; Zhou C; Yang H
    Mol Ther; 2023 Jul; 31(7):2286-2295. PubMed ID: 36805082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome.
    Lee D; Chen W; Kaku HN; Zhuo X; Chao ES; Soriano A; Kuncheria A; Flores S; Kim JH; Rivera A; Rigo F; Jafar-Nejad P; Beaudet AL; Caudill MS; Xue M
    Elife; 2023 Jan; 12():. PubMed ID: 36594817
    [No Abstract]   [Full Text] [Related]  

  • 13. CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice.
    Schmid RS; Deng X; Panikker P; Msackyi M; Breton C; Wilson JM
    J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33411694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model.
    Meng L; Person RE; Huang W; Zhu PJ; Costa-Mattioli M; Beaudet AL
    PLoS Genet; 2013; 9(12):e1004039. PubMed ID: 24385930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the
    Dindot SV; Christian S; Murphy WJ; Berent A; Panagoulias J; Schlafer A; Ballard J; Radeva K; Robinson R; Myers L; Jepp T; Shaheen H; Hillman P; Konganti K; Hillhouse A; Bredemeyer KR; Black L; Douville J; ;
    Sci Transl Med; 2023 Mar; 15(688):eabf4077. PubMed ID: 36947593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapies in preclinical and clinical development for Angelman syndrome.
    Markati T; Duis J; Servais L
    Expert Opin Investig Drugs; 2021 Jul; 30(7):709-720. PubMed ID: 34112038
    [No Abstract]   [Full Text] [Related]  

  • 17. A placebo-controlled trial of folic acid and betaine in identical twins with Angelman syndrome.
    Han J; Bichell TJ; Golden S; Anselm I; Waisbren S; Bacino CA; Peters SU; Bird LM; Kimonis V
    Orphanet J Rare Dis; 2019 Oct; 14(1):232. PubMed ID: 31640736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal delivery of a therapeutic antisense oligonucleotide achieves broad biodistribution in the brain and ameliorates Angelman syndrome phenotype in mice.
    Clarke MT; Remesal L; Lentz L; Tan DJ; Young D; Thapa S; Namuduri SR; Borges B; Kirn G; Valencia J; Lopez ME; Lui JH; Shiow LR; Dindot S; Villeda S; Sanders SJ; MacKenzie TC
    Mol Ther; 2024 Apr; 32(4):935-951. PubMed ID: 38327047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA.
    Wolter JM; Mao H; Fragola G; Simon JM; Krantz JL; Bazick HO; Oztemiz B; Stein JL; Zylka MJ
    Nature; 2020 Nov; 587(7833):281-284. PubMed ID: 33087932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
    Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y
    J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.